Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) insider Darlene Noci sold 1,604 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $17.03, for a total value of $27,316.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Darlene Noci also recently made the following trade(s):

• On Friday, July 15th, Darlene Noci sold 3,782 shares of Nuvalent stock. The stock was sold at an average price of $17.29, for a total value of $65,390.78.
• On Monday, July 18th, Darlene Noci sold 100 shares of Nuvalent stock. The stock was sold at an average price of $17.07, for a total value of $1,707.00.
• On Thursday, July 7th, Darlene Noci sold 16,800 shares of Nuvalent stock. The stock was sold at an average price of $17.61, for a total value of $295,848.00.

Nuvalent Trading Down 3.4 %

Shares of Nuvalent stock opened at $16.88 on Friday. The business's fifty day simple moving average is $15.47 and its 200 day simple moving average is $13.34. Nuvalent, Inc. has a 12 month low of $7.09 and a 12 month high of $40.82.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Nuvalent by 115.6% during the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after purchasing an additional 877,835 shares during the last quarter. Fairmount Funds Management LLC grew its position in Nuvalent by 46.3% in the first quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock worth $18,590,000 after acquiring an additional 423,779 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvalent by 9,445.3% in the fourth quarter. JPMorgan Chase & Co. now owns 391,645 shares of the company's stock worth $7,457,000 after purchasing an additional 387,542 shares during the last quarter. BlackRock Inc. lifted its stake in Nuvalent by 30.2% in the first quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock worth $17,466,000 after purchasing an additional 291,821 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Nuvalent during the second quarter valued at approximately $3,523,000.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets assumed coverage on Nuvalent in a research report on Thursday, June 23rd. They issued an "outperform" rating and a $28.00 target price for the company.

Nuvalent Company Profile

(Get Rating)

Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.

Featured Stories

• Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
• 3 Reasons Dollar General's Rally Has Legs
• Salesforce Stock Could Have Long Term Potential After Earnings
• Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
• Is PayPal A Buy After Post-Earnings Price Jump?
• Williams-Sonoma's High-End Consumers Are Still Spending

Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.